These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 30312409

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. In Vitro Susceptibility of Burkholderia cepacia Complex Isolated from Cystic Fibrosis Patients to Ceftazidime-Avibactam and Ceftolozane-Tazobactam.
    Van Dalem A, Herpol M, Echahidi F, Peeters C, Wybo I, De Wachter E, Vandamme P, Piérard D.
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914964
    [Abstract] [Full Text] [Related]

  • 3. "Switching Partners": Piperacillin-Avibactam Is a Highly Potent Combination against Multidrug-Resistant Burkholderia cepacia Complex and Burkholderia gladioli Cystic Fibrosis Isolates.
    Zeiser ET, Becka SA, Wilson BM, Barnes MD, LiPuma JJ, Papp-Wallace KM.
    J Clin Microbiol; 2019 Aug; 57(8):. PubMed ID: 31167848
    [Abstract] [Full Text] [Related]

  • 4. Comment on: In vitro activity of seven β-lactams including ceftolozane/tazobactam and ceftazidime/avibactam against Burkholderia cepacia complex, Burkholderia gladioli and other non-fermentative Gram-negative bacilli isolated from cystic fibrosis patients.
    Baklouti S, Massip C, Mane C, Guet-Revillet H, Murris M, Concordet D, Gandia P.
    J Antimicrob Chemother; 2019 Oct 01; 74(10):3122-3123. PubMed ID: 31335940
    [No Abstract] [Full Text] [Related]

  • 5. In Vitro Activity of Ceftolozane-Tazobactam and Other Antimicrobial Agents against Burkholderia cepacia Complex and Burkholderia gladioli.
    Mazer DM, Young C, Kalikin LM, Spilker T, LiPuma JJ.
    Antimicrob Agents Chemother; 2017 Sep 01; 61(9):. PubMed ID: 28674053
    [Abstract] [Full Text] [Related]

  • 6. Comparison of ceftazidime-avibactam and ceftolozane-tazobactam in vitro activities when tested against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017-2018).
    Sader HS, Flamm RK, Carvalhaes CG, Castanheira M.
    Diagn Microbiol Infect Dis; 2020 Mar 01; 96(3):114833. PubMed ID: 31924426
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Phylogenetic analysis of resistance to ceftazidime/avibactam, ceftolozane/tazobactam and carbapenems in piperacillin/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patients.
    Zamudio R, Hijazi K, Joshi C, Aitken E, Oggioni MR, Gould IM.
    Int J Antimicrob Agents; 2019 Jun 01; 53(6):774-780. PubMed ID: 30831233
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Susceptibility of Ceftolozane-Tazobactam and Ceftazidime-Avibactam Against a Collection of β-Lactam-Resistant Gram-Negative Bacteria.
    Gonzalez MD, McMullen AR, Wallace MA, Crotty MP, Ritchie DJ, Burnham CA.
    Ann Lab Med; 2017 Mar 01; 37(2):174-176. PubMed ID: 28029009
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
    Alatoom A, Elsayed H, Lawlor K, AbdelWareth L, El-Lababidi R, Cardona L, Mooty M, Bonilla MF, Nusair A, Mirza I.
    Int J Infect Dis; 2017 Sep 01; 62():39-43. PubMed ID: 28610832
    [Abstract] [Full Text] [Related]

  • 17. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG, Golden AR, Zelenitsky S, Wiebe K, Lawrence CK, Adam HJ, Idowu T, Domalaon R, Schweizer F, Zhanel MA, Lagacé-Wiens PRS, Walkty AJ, Noreddin A, Lynch Iii JP, Karlowsky JA.
    Drugs; 2019 Feb 01; 79(3):271-289. PubMed ID: 30712199
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. In vitro activity of β-lactams in combination with avibactam against multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Achromobacter xylosoxidans isolates from patients with cystic fibrosis.
    Mathy V, Grohs P, Compain F.
    J Med Microbiol; 2018 Sep 01; 67(9):1217-1220. PubMed ID: 30016231
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates.
    Buehrle DJ, Shields RK, Chen L, Hao B, Press EG, Alkrouk A, Potoski BA, Kreiswirth BN, Clancy CJ, Nguyen MH.
    Antimicrob Agents Chemother; 2016 May 01; 60(5):3227-31. PubMed ID: 26976862
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.